• Prescribing Information
  • Medical Information
  • Patient Site
  • Order Prevnar 20TM

  • Clinical studies


    ​​​​​​​PCV13=Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]); 
    PPSV23=23-valent pneumococcal polysaccharide vaccine.

    ​​​​​​​GMT=geometric mean titer; IPD=invasive pneumococcal disease; OPA=opsonophagocytic activity.
    ​​​​​​​

    Demonstrated immunogenicity* across adult populations1

    Noninferior immunogenicity compared to Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) and PPSV23 for shared serotypes1

    Immunogenicity for 20 serotypes in Prevnar 20™ measured in pneumococcal vaccine-naïve adults 60 years of age and older

    The effectiveness of Prevnar 20™ in adults 18-49 and 50-59 years of age was inferred by comparing the immune response to each of the 20 vaccine serotypes in these age groups (immunobridging) to the immune responses in adults 60-64 years of age.

    • Immune responses elicited by Prevnar 20™ (n=1157-1430) met noninferiority criteria for all shared serotypes with Prevnar 13® (n=1390-1419) and 6 of 7 shared serotypes with PPSV23 (n=1201-1319). The response to serotype 8 missed the prespecified statistical noninferiority criterion by a small margin (the lower bound of the 2-sided 95% CI for the GMT ratio being 0.49 versus >0.50).  In supportive analyses, 77.8% of participants in the Prevnar 20 group achieved a ≥4-fold rise in serotype 8 OPA titers from before vaccination to 1 month post-vaccination.

    GMFR=geometric mean fold rise; GMT=geometric mean titer; OPA=opsonophagocytic activity; PPSV23=23-valent pneumococcal polysaccharide vaccine.
    *OPA GMTs 1 month after vaccination with Prevnar 20™ vs control vaccine.
    PPSV23 and Prevnar 20™ have 19 shared serotypes. The 7 shared serotypes evaluated are unique to PPSV23 and Prevnar 20™, and are not contained in Prevnar 13®. 
    ​​​​​​​

    Safety profile for pneumococcal-vaccine naïve adults1

    Percentage of participants in Study 1 with solicited adverse reactions within 7-10 days after vaccination in pneumococcal vaccine-naïve adults*

    PCV13=Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]); PPSV23=23-valent pneumococcal polysaccharide vaccine.
    *Study 1 was conducted in the U.S. and in Sweden. n=number of participants with any e-diary data reported after vaccination (after Vaccination 1 [Prevnar 20™ or PCV13] for Study 1 participants 60 years of age and older). This value is the denominator for the percentage calculations. Local reactions measured within 10 days after vaccination; systemic reactions measured within 7 days after vaccination. §Includes all participants who reported a reaction as mild, moderate, or severe during Day 1 to Day 10 after vaccination. Diameters were measured in caliper units (0.5 cm) of whole numbers from 1 to 21 or 21+. Measurements were rounded up to the nearest whole number. Intensity of redness and swelling was characterized as: mild is >2.0 to 5.0 cm; moderate is >5.0 to 10.0 cm; severe is >10.0 cm. ||“Any local reaction” includes all participants who reported any injection site reaction (pain, swelling, or redness) as mild, moderate, or severe during Day 1 to Day 10 after vaccination. **Includes all participants who reported a reaction as mild, moderate, or severe during Day 1 to Day 7 after vaccination. ††“Any systemic reaction” includes all participants who reported any fever ≥38°C or any other systemic reaction (fatigue, headache, joint pain, or muscle pain) as mild, moderate, or severe during Day 1 to Day 7 after vaccination. ‡‡Severity was not collected for use of antipyretic or pain medication. The numbers listed reflect  “yes” responses (i.e., number of reactions reported). 
    ​​​​​​​

    Prevnar 20™ was studied in adults 65 and older who previously received pneumococcal pneumonia vaccination1

    Pneumococcal OPA GMTs were evaluated before and 1 month after administration of Prevnar 20™ in adults 65 years of age and older with prior pneumococcal vaccination


    • This randomized, open-label clinical trial described immune responses to Prevnar 20™ in adults 65 years of age and older previously vaccinated with PPSV23, or PCV13 or PCV13 followed by PPSV23
    PCV13=Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]); PPSV23=23-valent pneumococcal polysaccharide vaccine.
    GMT=geometric mean titer; OPA=opsonophagocytic activity.
    ​​​​​​​
    ​​​​​​​

    ​​​​​​​

    ​​​​​​​Safety profile for adults with previous pneumococcal vaccination

    Percentage of participants in Study 1006 with solicited adverse reactions within 7-10 days after vaccination in adults 65 years of age and older by prior pneumococcal vaccination status*†

    PCV13=Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]); PPSV23=23-valent pneumococcal polysaccharide vaccine.
    *Study 6 was conducted in the U.S. and in Sweden. Open-label administration of Prevnar 20™. Includes participants who previously received either PPSV23 ≥1 to ≤5 years before enrollment, PCV13 ≥6 months before enrollment, or PCV13 followed by PPSV23 ≥1 year before enrollment in the study. §n=number of participants with any e-diary data reported after vaccination. This value is the denominator for the percentage calculations. Local reactions measured within 10 days after vaccination; systemic reactions measured within 7 days after vaccination. ||Includes all participants who reported a reaction as mild, moderate, or severe during Day 1 to Day 10 after vaccination. **Diameters were measured in caliper units (0.5 cm) of whole numbers from 1 to 21 or 21+. Measurements were rounded up to the nearest whole number. Intensity of redness and swelling was characterized as: mild is >2.0 to 5.0 cm; moderate is >5.0 to 10.0 cm; severe is >10.0 cm. ††“Any local reaction” includes all participants who reported any injection site reaction (pain, swelling, or redness) as mild, moderate, or severe during Day 1 to Day 10 after vaccination. ‡‡Includes all participants who reported a reaction as mild, moderate, or severe during Day 1 to Day 7 after vaccination. §§”Any systemic reaction” includes all participants who reported any fever ≥38°C or any other systemic reaction (fatigue, headache, joint pain, or muscle pain) as mild, moderate, or severe during Day 1 to Day 7 after vaccination. ¶¶Severity was not collected for use of antipyretic or pain medication. The numbers listed reflect “yes” responses (i.e., number of reactions reported).


    References: 1. Prevnar 20™ (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information, Wyeth Pharmaceuticals LLC, 2021. 2. Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) Prescribing Information, Wyeth Pharmaceuticals LLC, 2019. 3. Poehling K, Kobayashi M for the Pneumococcal Work Group. Introduction of the Pneumococcal Work Group. Presented at: Advisory Committee on Immunization Practices; October 28, 2020. Accessed February 5, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-10/pneumo-01-Poehling-Kobayashi-508.pdf 4. Grant LR, Ramirez J, Self WH, et al. Streptococcus pneumoniae Serotype Distribution and Coverage of Pneumococcal Conjugate Vaccines in Adults Hospitalized with Community-Acquired Pneumonia in the United States. ISPPD. 2020; abstract #879. Accessed February 5, 2021. https://cslide.ctimeetingtech.com/isppd20/attendee/confcal/presentation/list?q=grant 

    Additional serotype protection

    With the most serotypes in a pneumococcal conjugate vaccine, you can help protect your patients from more disease.1-4

    See the coverage difference

    Built on an established vaccine

    Prevnar 20™ was designed to expand on the efficacy of Prevnar 13®.1

    Review the data

    This site is intended only for US residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

    ​​​​​Manufactured by Wyeth Pharmaceuticals LLC.
    © 2021 Pfizer Inc.

    ​​​​​​​​​​​​All rights reserved.

    Marketed by Pfizer Inc.
    November 2021

    ​​​​​Manufactured by Wyeth Pharmaceuticals LLC.
    Marketed by Pfizer Inc.
    © 2021 Pfizer Inc. ​​​​​All rights reserved. November 2021

    Indication

    • Prevnar 20™ is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older
    • This indication for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial 
      ​​​​​​​
      • Severe allergic reaction (e.g., anaphylaxis) to any component of Prevnar 20™, Prevnar 13®, or to diphtheria toxoid is a contraindication
      • Safety and immunogenicity data on Prevnar 20™ are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20™
      • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response to Prevnar 13®
      • For Prevnar 20™, in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>10%) were pain at the injection site, muscle pain, fatigue, headache, and arthralgia. Additionally, injection site swelling was also reported (>10%) in adults 18 through 59 years of age 
      • For Prevnar 13®, in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>5%) were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash 

      Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

      Please click for Prevnar 20™ Full Prescribing Information.

      Please click for Prevnar 13® Full Prescribing Information.


      • Prevnar 20™ is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older 
      • The indication of Prevnar 20™ for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial 
      • Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older

      Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine